Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CD70-targeted CAR-T cells · 1 trial · 6 indications
Incidence of adverse events during the study, evaluated per the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 and American Society for Transplantation and Cellular Therapy (ASTCT) criteria
Dose-limiting toxicity after CD70 CAR-T cell infusion
| Arm | Type | Description |
|---|---|---|
| Intravenous of CD70-targeted CAR-T | EXPERIMENTAL | Infusion of CD70-targeted CAR-T cells by dose of 3-10x10\^5 cells/kg |
| Intrapleural infusion of CD70-targeted CAR-T | EXPERIMENTAL | Infusion of CD70-targeted CAR-T cells by dose of 3-10x10\^5 cells/kg |
| Intraperitoneal infusion of CD70-targeted CAR-T | EXPERIMENTAL | Infusion of CD70-targeted CAR-T cells by dose of 3-10x10\^5 cells/kg |
| Name | Type | Description |
|---|---|---|
| CD70-targeted CAR-T cells | BIOLOGICAL | Administration method: intravenous infusion. Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion. |
Inclusion Criteria: 1. Age ≥18 years, regardless of gender; 2. Histologically or cytologically confirmed advanced/metastatic solid tumors (tumors with positive CD70 expression, confirmed histopathological ly with IHC 3+ score); 3. Failed or intolerant to standard second-line treatments (at least on...
CD70-targeted CAR-T cells is an investigational cell therapy being developed for CD70-positive advanced solid tumors, with a primary focus on Renal Cell Carcinoma (RCC). The therapy is also being studied in lung cancer, anaplastic thyroid carcinomas, ovarian cancer, cervical cancer, and thymic carcinoma.
Precision BioSciences, Inc. (NASDAQ: DTIL) is developing CD70-targeted CAR-T cells. The company is conducting a Phase 1 clinical trial of this investigational therapy in patients with CD70-positive advanced solid tumors.
CD70-targeted CAR-T cells is in Phase 1 clinical development. It is an investigational therapy and has not been approved by regulatory authorities. The ongoing Phase 1 trial is currently recruiting participants.
CD70-targeted CAR-T cells is being evaluated in a single Phase 1 clinical trial, NCT07181720, titled 'CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors.' The trial is recruiting 90 participants in China and is not randomized or double-blinded.
CD70-targeted CAR-T cells are engineered to recognize and attack cells expressing the CD70 antigen, a protein found on certain tumor cells. By targeting CD70, the therapy aims to direct the patient's own immune cells to destroy CD70-positive cancer cells in solid tumors.